Clinical Trials · NCT00196846
Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- GBG Forschungs GmbH
- Enrollment
- 62
- Start date
- Mar 2005
- Locations
- 1 site, Germany
- Primary endpoint
- Normal ovarian function as defined by two consecutive menstrual periods within 21-35 days within a time frame of 5 - 8 months after last application of goserelin